London-based Palta, which develops health and wellness apps, raises $100M Series B led by Per Brillioth at VNV Global
Context & Ripple Effects
Palta's $100M Series B lands in the middle of a sustained London digital-health funding run: Babylon set an early marker with its $25M Series A in 2016, Privitar raised $80M in 2020, and UK peer Oviva followed Palta within weeks with its own $80M Series C. The later rounds from Patient21 and Peppy show the wave kept building well past 2021.
The round also fits Dealroom's finding that London reclaimed its position as Europe's leading tech hub — health and wellness apps are one of the sectors where the city's funding depth is most visible, and a nine-figure Series B for an app portfolio developer is a strong data point for that claim.
First-order effects
- Palta gains $100M to build out its portfolio of health and wellness apps, with VNV Global's Per Brillioth taking the lead-investor role and signaling institutional conviction in consumer health app platforms.
Second-order effects
- Oviva's $80M Series C weeks later shows the round fed a broader UK health-app funding momentum rather than being an isolated bet, and Peppy's later $45M Series B extended the pattern into B2B2C health services.
Third-order effects
- If the cadence holds, London consolidates as Europe's health-tech funding center, with capital migrating from pure consumer apps toward hybrid models like Patient21's digital platform plus physical clinics.
The trend: London's digital-health sector is compounding through successive large rounds — from Babylon in 2016 to Palta and Oviva in 2021 and Peppy and Patient21 after — cementing the city as Europe's health-tech funding hub.